Role of zoledronic acid in the prevention and treatment of osteoporosis

References

• EastellRBlackDMBoonenSEffect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral densityJ Clin Endocrinol Metab20099493215322519567517
   PubMed Web of Science ®Google Scholar
• National Osteoporosis FoundationClinician’s Guide to Prevention and Treatment of OsteoporosisWashington, DCNational Osteoporosis Foundation2008
   Google Scholar
• HanleyDAJosseRGPrevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 1. IntroductionCMAJ199615579219238837540
   PubMed Web of Science ®Google Scholar
• PapadimitropoulosEACoytePCJosseRGGreenwoodCECurrent and projected rates of hip fracture in CanadaCMAJ199715710135713639371065
   PubMed Web of Science ®Google Scholar
• National Institutes of Health Consensus Development Panel on Osteoporosis, Prevention, Diagnosis and TherapyOsteoporosis prevention, diagnosis, and therapyJAMA2001285678579511176917
   PubMed Web of Science ®Google Scholar
• GenantHKCooperCPoorGInterim report and recommendations of the World Health OrganizationTask-Force for OsteoporosisOsteoporos Int199910425926410692972
   PubMed Web of Science ®Google Scholar
• JohnellOKanisJAOdenAPredictive value of BMD for hip and other fracturesJ Bone Miner Res20052071185119415940371
   PubMed Web of Science ®Google Scholar
• CauleyJAThompsonDEEnsrudKCRisk of mortality following clinical fracturesOsteoporos Int200011755656111069188
   PubMed Web of Science ®Google Scholar
• ChrischillesEAButlerCDDavisCSWallaceRBA model of lifetime osteoporosis impactArch Intern Med199115110202620321929691
   PubMedGoogle Scholar
• PapaioannouAMorinSCheungAM2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summaryCMAJ2010182171864187320940232
   PubMed Web of Science ®Google Scholar
• BrownJPJosseRG2002 clinical practice guidelines for the diagnosis and management of osteoporosis in CanadaCMAJ2002167901001S34S
   Google Scholar
• KanisJOdenAJohnellOThe use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and womenOsteoporosis Int200718810331046
   PubMed Web of Science ®Google Scholar
• SiminoskiKLeslieWDFrameHRecommendations for bone mineral density reporting in CanadaCan Assoc Radiol J200556317818816144280
   PubMed Web of Science ®Google Scholar
• YinMTShiQHooverDRFracture incidence in HIV-infected women: results from the Women’s Interagency HIV StudyAIDS201024172679268620859192
   PubMed Web of Science ®Google Scholar
• GertzBJHollandSDKlineWFStudies of the oral bioavailability of alendronateClin Pharmacol Ther19955832882987554702
   PubMed Web of Science ®Google Scholar
• BrookhartMAAvornJKatzJNGaps in treatment among users of osteoporosis medications: the dynamics of noncomplianceAm J Med2007120325125617349448
   PubMed Web of Science ®Google Scholar
• SirisESHarrisSTRosenCJAdherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databasesMayo Clin Proc20068181013102216901023
   PubMed Web of Science ®Google Scholar
• LiECDavisLEZoledronic acid: a new parenteral bisphosphonateClin Ther200325112669270814693298
   PubMed Web of Science ®Google Scholar
• NancollasGHTangRPhippsRJNovel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatiteBone200638561762716046206
   PubMed Web of Science ®Google Scholar
• DunfordJEThompsonKCoxonFPStructure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonatesJ Pharmacol Exp Ther2001296223524211160603
   PubMed Web of Science ®Google Scholar
• CoxonFPHelfrichMHVan’t HofRProtein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298J Bone Miner Res20001581467147610934645
   PubMed Web of Science ®Google Scholar
• ChenTBerensonJVescioRPharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastasesJ Clin Pharmacol200242111228123612412821
   PubMed Web of Science ®Google Scholar
• PietrzikKBaileyLShaneBFolic acid and L-5-methyltetrahydrofolate: comparison of clinical pharmacokinetics and pharmacodynamicsClin Pharmacokinet201049853554820608755
   PubMed Web of Science ®Google Scholar
• SkerjanecABerensonJHsuCThe pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal functionJ Clin Pharmacol200343215416212616668
   PubMed Web of Science ®Google Scholar
• BlackDMDelmasPDEastellROnce-yearly zoledronic acid for treatment of postmenopausal osteoporosisN Engl J Med2007356181809182217476007
   PubMed Web of Science ®Google Scholar
• SaagKLindsayRKriegmanAA single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral densityBone20074051238124317347063
   PubMed Web of Science ®Google Scholar
• DelmasPDMunozFBlackDMEffects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosisJ Bone Miner Res20092491544155119338427
   PubMed Web of Science ®Google Scholar
• BoonenSBlackDMColon-EmericCSEfficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and olderJ Am Geriatr Soc201058229229920070415
   PubMed Web of Science ®Google Scholar
• McClungMReckerRMillerPIntravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronateBone200741112212817468062
   PubMed Web of Science ®Google Scholar
• ReckerRRDelmasPDHalseJEffects of intravenous zoledronic acid once yearly on bone remodeling and bone structureJ Bone Miner Res200823161617892374
   PubMed Web of Science ®Google Scholar
• EastellRLangTBoonenSEffect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture TrialOsteoporos Int20102171277128519802508
   PubMed Web of Science ®Google Scholar
• GamsjaegerSBuchingerBZwettlerEBone material properties in actively bone-forming trabeculae in postmenopausal women with osteoporosis after three years of treatment with once-yearly zoledronic acidJ Bone Miner Res20102529229719821769
   PubMed Web of Science ®Google Scholar
• McClungMMillerPRecknorCZoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trialObstet Gynecol20091145999100720168099
   PubMed Web of Science ®Google Scholar
• GreyABollandMJWattieDThe antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal womenJ Clin Endocrinol Metab200994253854419050050
   PubMed Web of Science ®Google Scholar
• LylesKWColon-EmericCSMagazinerJSZoledronic acid and clinical fractures and mortality after hip fractureN Engl J Med2007357181799180917878149
   PubMed Web of Science ®Google Scholar
• BoonenSMJLylesKColon-EmericCEffect of once- yearly i.v. zoledronic acid in men after hip fracture: results from the HORIZON-Recurrent Fracture TrialOsteoporos Int200920Suppl 1S23S176
   Google Scholar
• ReidDMDevogelaerJPSaagKZoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trialLancet200937396711253126319362675
   PubMed Web of Science ®Google Scholar
• OrwollESMillerPDAdachiJDEfficacy and safety of a once-yearly i.v. infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled studyJ Bone Miner Res201025102239225020499357
   PubMed Web of Science ®Google Scholar
• RossRWSmallEJOsteoporosis in men treated with androgen deprivation therapy for prostate cancerJ Urol200216751952195611956415
   PubMed Web of Science ®Google Scholar
• SmithMREasthamJGleasonDMRandomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancerJ Urol200316962008201212771706
   PubMed Web of Science ®Google Scholar
• BhoopalamNCampbellSCMoritzTIntravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapyJ Urol200918252257226419758618
   PubMed Web of Science ®Google Scholar
• NeviaserASLaneJMLenartBALow-energy femoral shaft fractures associated with alendronate useJ Orthop Trauma200822534635018448990
   PubMed Web of Science ®Google Scholar
• LenartBALorichDGLaneJMAtypical fractures of the femoral diaphysis in postmenopausal women taking alendronateN Engl J Med2008358121304130618354114
   PubMed Web of Science ®Google Scholar
• KwekEBGohSKKohJSAn emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?Injury200839222423118222447
   PubMed Web of Science ®Google Scholar
• GohSKYangKYKohJSSubtrochanteric insufficiency fractures in patients on alendronate therapy: a cautionJ Bone Joint Surg Br200789334935317356148
   PubMedGoogle Scholar
• GiustiAHamdyNAPapapoulosSEAtypical fractures of the femur and bisphosphonate therapy: a systematic review of case/case series studiesBone201047216918020493982
   PubMed Web of Science ®Google Scholar
• ShaneEBurrDEbelingPRAtypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral ResearchJ Bone Miner Res201025112267229420842676
   PubMed Web of Science ®Google Scholar
• RizzoliRAkessonKBouxseinMSubtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group ReportOsteoporos Int2011222373390 Epub November 18, 2010.21085935
   PubMed Web of Science ®Google Scholar
• FDAInformation on bisphosphonates (marketed as Actonel, Actonel+Ca, Aredia, Boniva, Didronel, Fosamax, Fosamax+D, Reclast, Skelid, and Zometa) http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm101551.htm. Accessed November 22, 2010.
   Google Scholar
• BlackDMKellyMPGenantHKBisphosphonates and fractures of the subtrochanteric or diaphyseal femurN Engl J Med2010362191761177120335571
   PubMed Web of Science ®Google Scholar
• WooSBHellsteinJWKalmarJRNarrative [corrected] review: bisphosphonates and osteonecrosis of the jawsAnn Intern Med20061441075376116702591
   PubMed Web of Science ®Google Scholar
• GrbicJTLandesbergRLinSQIncidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trialJ Am Dent Assoc20081391324018167382
   PubMed Web of Science ®Google Scholar
• PazianasMMillerPBlumentalsWAA review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristicsClin Ther20072981548155817919538
   PubMed Web of Science ®Google Scholar
• BucklerHFraserWHoskingDSingle infusion of zoledronate in Paget’s disease of bone: a placebo-controlled, dose-ranging studyBone1999245 Suppl81S85S10321935
   PubMed Web of Science ®Google Scholar
• ReidIRBrownJPBurckhardtPIntravenous zoledronic acid in postmenopausal women with low bone mineral densityN Engl J Med2002346965366111870242
   PubMed Web of Science ®Google Scholar
• BoonenSSellmeyerDELippunerKRenal safety of annual zoledronic acid infusions in osteoporotic postmenopausal womenKidney Int200874564164818509324
   PubMed Web of Science ®Google Scholar
• WeinmanEJPatakRVAcute renal failure in cancer patientsOncology (Williston Park)1992694752 discussion 52–441449976
   PubMedGoogle Scholar
• KintzelPEAnticancer drug-induced kidney disordersDrug Saf2001241193811219485
   PubMed Web of Science ®Google Scholar
• Health CanadaUpdated Renal Safety Information on Zometa (Zoledronic Acid) and Aclasta (Zoledronic Acid) http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/public/_2005/zometa_aclasta_pa-ap-eng.php. Accessed January 24, 2011.
   Google Scholar
• OrwollESOsteoporosis in menPrimer on the Metabolic Bone Diseases and Disorders of Mineral MetabolismFavusMJWashington, CDAmerican Society for Bone and Mineral Research2003360364
   Google Scholar
• OrwollEMillerPAdachiJOnce-yearly IV zoledronic acid 5 mg versus weekly oral alendronate 70 mg in men with osteoporosisENDO 2009 Abstracts2View Online Abstract OR13-3Chevy Chase, MDThe Endocrine Society2009 http://www.endo-society.org/endo09/. Accessed January 24, 2011.
   Google Scholar
• McCombsJSThiebaudPMcLaughlin-MileyCShiJCompliance with drug therapies for the treatment and prevention of osteoporosisMaturitas20044837128715223111
   PubMed Web of Science ®Google Scholar